These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18537574)

  • 21. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.
    Lai XS; Yang LP; Li XT; Liu JP; Zhou ZW; Zhou SF
    Curr Drug Metab; 2009 Nov; 10(9):1009-47. PubMed ID: 20214592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of ethnic differences in drug disposition and response.
    Xie HG; Kim RB; Wood AJ; Stein CM
    Annu Rev Pharmacol Toxicol; 2001; 41():815-50. PubMed ID: 11264478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression variability in human hepatic drug metabolizing enzymes and transporters.
    Yang L; Price ET; Chang CW; Li Y; Huang Y; Guo LW; Guo Y; Kaput J; Shi L; Ning B
    PLoS One; 2013; 8(4):e60368. PubMed ID: 23637747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphisms in drug-metabolizing enzymes and drug targets.
    Hiratsuka M; Mizugaki M
    Mol Genet Metab; 2001 Aug; 73(4):298-305. PubMed ID: 11509011
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulation of drug-metabolizing enzymes and transporters in inflammation.
    Aitken AE; Richardson TA; Morgan ET
    Annu Rev Pharmacol Toxicol; 2006; 46():123-49. PubMed ID: 16402901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro.
    van de Kerkhof EG; de Graaf IA; Ungell AL; Groothuis GM
    Drug Metab Dispos; 2008 Mar; 36(3):604-13. PubMed ID: 18094037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [General pharmacodynamic principles].
    Bernard JP; Opdal MS; Khiabani H
    Tidsskr Nor Laegeforen; 2006 Aug; 126(16):2107-9. PubMed ID: 16932780
    [No Abstract]   [Full Text] [Related]  

  • 28. Unusual commonality in active site structural features of substrate promiscuous and specialist enzymes.
    Thakur D; Pandit SB
    J Struct Biol; 2022 Mar; 214(1):107835. PubMed ID: 35104611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF; Jacobs MN; Dickins M
    Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions.
    Brunelle A; Bi YA; Lin J; Russell B; Luy L; Berkman C; Cashman J
    Drug Metab Dispos; 1997 Aug; 25(8):1001-7. PubMed ID: 9280409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transporters and drug therapy: implications for drug disposition and disease.
    Ho RH; Kim RB
    Clin Pharmacol Ther; 2005 Sep; 78(3):260-77. PubMed ID: 16153397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
    Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
    Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme kinetics in drug metabolism: fundamentals and applications.
    Nagar S; Argikar UA; Tweedie DJ
    Methods Mol Biol; 2014; 1113():1-6. PubMed ID: 24523105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug disposition in pathophysiological conditions.
    Gandhi A; Moorthy B; Ghose R
    Curr Drug Metab; 2012 Nov; 13(9):1327-44. PubMed ID: 22746301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
    Kalitsky-Szirtes J; Shayeganpour A; Brocks DR; Piquette-Miller M
    Drug Metab Dispos; 2004 Jan; 32(1):20-7. PubMed ID: 14709616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of human drug metabolizing enzyme induction.
    Mankowski DC; Ekins S
    Curr Drug Metab; 2003 Oct; 4(5):381-91. PubMed ID: 14529370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.
    Dong D; Wu B
    Drug Metab Rev; 2012 Feb; 44(1):1-17. PubMed ID: 22242930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-metabolizing enzymes in ligand-modulated transcription.
    Nebert DW
    Biochem Pharmacol; 1994 Jan; 47(1):25-37. PubMed ID: 8311842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolution of drug metabolism.
    Nebert DW; Dieter MZ
    Pharmacology; 2000 Sep; 61(3):124-35. PubMed ID: 10971198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.